Advertisement
Advertisement

DVAX

DVAX logo

Dynavax Technologies Corporation

10.30
USD
-0.35
-3.31%
Apr 17, 15:59 UTC -4
Closed
exchange

After-Market

10.23

-0.06
-0.60%

Dynavax Technologies Corporation Profile

About

Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.

Info & Links

CEO

Ryan Spencer

Headquarters

2100 Powell Street, Suite 720
Emeryville, CA 94608, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.dynavax.com

Auditor

Ernst & Young LLP

Share holders

39

Employees

405

Dynavax Technologies Corporation Statistics

Valuation Measures

Market Capitalization2

1.27B

Enterprise Value

1.40B

Enterprise Value/EBITDA(ttm)

-131.68

Price to Earnings Ratio(ttm)

74.06

Price to Sales(ttm)

6.32

Price to Book(mrq)

2.56

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

81.83%

Operating Margin(ttm)

9.85%

Profit Margin(ttm)

7.47%

Return on Equity(ttm)

4.22%

Return on Invested Capital(ttm)

3.08%

Return on Assets(ttm)

2.67%

Income Statement

Revenue(ttm)

277.25M

Revenue Per Share(ttm)

2.23

Gross Profit(ttm)

227.80M

EBITDA(ttm)3

-10.62M

Net Income Available to Common(ttm)

27.31M

Diluted EPS(ttm)

0.18

Share Statistics

Beta (5Y Monthly)

1.32

52-Week Change

-9.91%

S&P 500 52-Week Change

6.35%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

124.07M

Dividend Yield

0.00%

Float4

127.54M

% Held by Insiders

2.98%

% Held by Institutions

96.96%

Balance Sheet

Total Cash(mrq)

713.83M

Total Cash Per Share(mrq)

5.75

Total Debt(mrq)

223.85M

Total Debt/Equity(mrq)

37.51%

Current Ratio(mrq)

10.80%

Quick Ratio(mrq)

12.34%

Book Value Per Share(mrq)

4.76

Cash Flow

Operating Cash Flow Per Share(ytd)

0.50

Free Cash Flow(ytd)

60.16M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement